BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33401002)

  • 21. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia.
    Ott K; Weber WA; Fink U; Helmberger H; Becker K; Stein HJ; Müller J; Schwaiger M; Siewert JR
    World J Surg; 2003 Sep; 27(9):1035-9. PubMed ID: 12917760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.
    Hu X; Wu L; Liu B; Chen K
    Front Immunol; 2021; 12():651056. PubMed ID: 34122409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological Significance of STAT3 and p-STAT3 among 91 Patients with Adenocarcinoma of the Esophagogastric Junction.
    Ma RJ; Zheng QM; Zhang N; Sun ZG
    Dis Markers; 2022; 2022():9311684. PubMed ID: 36225196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction.
    von Rahden BH; Stein HJ; Feith M; Becker K; Siewert JR
    J Clin Oncol; 2005 Feb; 23(4):874-9. PubMed ID: 15681533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction.
    Aratani K; Komatsu S; Ichikawa D; Ohashi T; Miyamae M; Okajima W; Imamura T; Kiuchi J; Nishibeppu K; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
    Anticancer Res; 2017 Jun; 37(6):3129-3135. PubMed ID: 28551654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative pre-albumin predicts prognosis of patients after gastrectomy for adenocarcinoma of esophagogastric junction.
    Han WX; Chen ZM; Wei ZJ; Xu AM
    World J Surg Oncol; 2016 Nov; 14(1):279. PubMed ID: 27809860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
    Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction.
    Li S; Li B; Wang J; Zhang D; Liu Z; Zhang Z; Zhang W; Wang Y; Bai D; Guan J; Zhang Y
    Oncol Res; 2017 Jan; 25(1):93-97. PubMed ID: 28081737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrative proteomic characterization of adenocarcinoma of esophagogastric junction.
    Li S; Yuan L; Xu ZY; Xu JL; Chen GP; Guan X; Pan GZ; Hu C; Dong J; Du YA; Yang LT; Ni MW; Jiang RB; Zhu X; Lv H; Xu HD; Zhang SJ; Qin JJ; Cheng XD
    Nat Commun; 2023 Feb; 14(1):778. PubMed ID: 36774361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
    Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
    Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
    [No Abstract]   [Full Text] [Related]  

  • 31. Unchanging trend of esophagogastric junction adenocarcinoma in Korea: experience at a single institution based on Siewert's classification.
    Chung JW; Lee GH; Choi KS; Kim DH; Jung KW; Song HJ; Choi KD; Jung HY; Kim JH; Yook JH; Kim BS; Jang SJ
    Dis Esophagus; 2009; 22(8):676-81. PubMed ID: 19222529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenocarcinoma of the esophagogastric junction and its background mucosal pathology: A comparative analysis according to Siewert classification in a Japanese cohort.
    Urabe M; Ushiku T; Shinozaki-Ushiku A; Iwasaki A; Yamazawa S; Yamashita H; Seto Y; Fukayama M
    Cancer Med; 2018 Oct; 7(10):5145-5154. PubMed ID: 30239168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
    Springfeld C; Wiecha C; Kunzmann R; Heger U; Weichert W; Langer R; Stange A; Blank S; Sisic L; Schmidt T; Lordick F; Jäger D; Grenacher L; Bruckner T; Büchler MW; Ott K
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S905-14. PubMed ID: 26001861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 35. Anti-angiogenic and antitumor activities of Huaier aqueous extract.
    Wang X; Zhang N; Huo Q; Yang Q
    Oncol Rep; 2012 Oct; 28(4):1167-75. PubMed ID: 22895629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
    Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
    Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency and clinical impact of lymph node micrometastasis and tumor cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction.
    Mueller JD; Stein HJ; Oyang T; Natsugoe S; Feith M; Werner M; Rüdiger Siewert J
    Cancer; 2000 Nov; 89(9):1874-82. PubMed ID: 11064343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Huaier aqueous extract inhibits ovarian cancer cell motility via the AKT/GSK3β/β-catenin pathway.
    Yan X; Lyu T; Jia N; Yu Y; Hua K; Feng W
    PLoS One; 2013; 8(5):e63731. PubMed ID: 23667667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Retrospect of 2019: focus on the surgical treatment for adenocarcinoma of esophagogastric junction].
    Yan CY; Chen LQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):20-25. PubMed ID: 31958926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study.
    Xu H; Zhang L; Miao J; Liu S; Liu H; Jia T; Zhang Q
    World J Surg Oncol; 2020 Jun; 18(1):144. PubMed ID: 32593312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.